Literature DB >> 7814245

Non-anticoagulation in atrial fibrillation.

J A O'Hare1, N Ul-Iman, M Geoghegan.   

Abstract

Atrial fibrillation (AF) is an important risk factor for stroke and anticoagulation is now indicated in many patients at increased risk. Studies however have shown that many patients at risk are not anticoagulated for reasons that are not well explored. We identified prospectively the reasons for non-anticoagulation in patients with AF in 94 consecutive hospital patients with cardiac or cerebrovascular disease who had AF. Patients with intermittent or lone AF and < 60 years were excluded n = 16. The remaining group had a mean age of 76 +/- 7 years with a mental test score of 7.4 +/- 2 (normal 10), 31 lived alone and they lived an average of 14 +/- 11 miles from the hospital laboratory. The reasons for non-anticoagulation overlapped and were: medical in 29: cognitive impairment/compliance in 32: and monitoring problems in 50. Anticoagulation for AF in the elderly is a complex enterprise which must take into account social and cognitive as well as medical issues.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7814245     DOI: 10.1007/bf02940563

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  15 in total

1.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.

Authors:  Daniel E Singer; Robert A Hughes; Daryl R Gress; Mary A Sheehan; Lynn B Oertel; Sue Ward Maraventano; Dyan Ryan Blewett; Bernard Rosner; J Philip Kistler
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

Review 2.  Management of atrial fibrillation.

Authors:  E L Pritchett
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

3.  Antithrombotic treatment and atrial fibrillation.

Authors:  J Barnaby; A J Howitt
Journal:  BMJ       Date:  1993-01-16

4.  Survey of use of anticoagulation in patients with atrial fibrillation.

Authors:  P M Bath; A Prasad; M M Brown; G A MacGregor
Journal:  BMJ       Date:  1993-10-23

5.  Warfarin in chronic atrial fibrillation.

Authors:  L E Ramsay
Journal:  Lancet       Date:  1993-05-29       Impact factor: 79.321

6.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

7.  Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions.

Authors:  C S Landefeld; M W Rosenblatt; L Goldman
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

8.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.

Authors:  S J Connolly; A Laupacis; M Gent; R S Roberts; J A Cairns; C Joyner
Journal:  J Am Coll Cardiol       Date:  1991-08       Impact factor: 24.094

9.  Stroke Prevention in Atrial Fibrillation Study. Final results.

Authors: 
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

10.  Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.

Authors:  S D Fihn; M McDonell; D Martin; J Henikoff; D Vermes; D Kent; R H White
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

View more
  1 in total

1.  Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?

Authors:  Tahmeed Contractor; Atul Khasnis
Journal:  Cardiol Res Pract       Date:  2011-03-30       Impact factor: 1.866

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.